TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02902575

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted gastrectomy with D2 lymphadenectomy
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic-assisted gastrectomy with D2 lymphadenectomy will be performed with curative treated intent.The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
Study: NCT03803696

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard Care
Description: * Baseline data collection, registration and randomization~* Inform primary transplant clinician of sexual dysfunction causing distress~* Receive American Cancer Society sexual educational material

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal Intervention to Address Sexual Dysfunction
Description: Baseline data collection, registration and randomization~- 3 Monthly visits with trained study nurse practitioners~* Referral to specialist if~* Psychological etiology~* Sexual Trauma~* Relationship Discord~* Concern for Malignancy or anatomic scarring requiring surgery
Study: NCT02452190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reslizumab
Description: Reslizumab will be administered subcutaneously in a dose of 110 mg every 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT04179682

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 40-hour constraint-induced movement therapy
Description: Participants were randomly allocated to 1 of 2 CIMT programs (40 hours): a 2-week 4-hours/day CIMT program and a 4-week 2-hours/day CIMT program. One CIMT program was performed 1 month after a BoNT-A injection, and then the second program was implemented with the next injection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 40-hour constraint-induced movement therapy
Description: Participants were randomly allocated to 1 of 2 CIMT programs (40 hours): a 2-week 4-hours/day CIMT program and a 4-week 2-hours/day CIMT program. One CIMT program was performed 1 month after a BoNT-A injection, and then the second program was implemented with the next injection.
Study: NCT02385890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Non pulse ingredient bagel

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea flour
Description: Pulse ingredient bagel

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea fibre
Description: Pulse ingredient bagel

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea protein
Description: Pulse ingredient bagel

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea flour + pea protein
Description: Pulse ingredient bagel

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea fibre + pea protein
Description: Pulse ingredient bagel
Study: NCT03111433

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: Coenzyme Q10 soft gelatin capsule 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: multiple dose insulin injection therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: multiple dose insulin injection therapy
Study: NCT01385644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placental MSC
Description: MSC will be derived from mothers donating their term placenta for clinical trial research purposes at Mater Mothers Hospital, Brisbane. The donation, isolation and expansion of placental-derived MSC for research purposes has been approved by the Mater Health Services (MHS) Human Research Ethics Committee (Reference No. 1292A). These volunteer donor mothers are unrelated to and will be HLA-unmatched with the IPF recipients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placental MSC
Description: MSC will be derived from mothers donating their term placenta for clinical trial research purposes at Mater Mothers Hospital, Brisbane. The donation, isolation and expansion of placental-derived MSC for research purposes has been approved by the Mater Health Services (MHS) Human Research Ethics Committee (Reference No. 1292A). These volunteer donor mothers are unrelated to and will be HLA-unmatched with the IPF recipients.
Study: NCT00675350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine
Description: 1.25 mg/m2 subcutaneous twice daily for 14 days
Study: NCT03803137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VOC analysis
Description: VOC analysis in exhaled air with e-noses and mass spectrometry
Study: NCT03236792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: 3 mg or 4mg of Ixazomib will be taken orally on days 1, 8, and 15 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300, 400, or 500 mg of oral Cyclophosphamide on days 1, 8, and 15 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg of oral Dexamethasone on days 1, 8, 15, 22 in a 28-day cycle
Study: NCT01337934

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactated Ringer
Description: Lactated Ringer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Description: Albumin 4%
Study: NCT00322036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPC-7869
Description: Oral 800 mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MPC-7869
Description: Oral BID dosing
Study: NCT04342169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: HCQ 400mg po BID x 1 day, then 200mg po BID x 4 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo to be taken on the same schedule as HCQ.
Study: NCT03781271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic Navigation
Description: Electromagnetic navigation is a form of surgical navigation that can be incorporated into the cervical interstitial brachytherapy workflow to improve the current standards of guidance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic Navigation
Description: Electromagnetic navigation is a form of surgical navigation that can be incorporated into the cervical interstitial brachytherapy workflow to improve the current standards of guidance.
Study: NCT02844478

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SBP English
Description: The SBP caregiver intervention has been successfully delivered and disseminated in the US. It is currently offered in 9 states and 16 Texas counties . The SBP is designed to a) improve the QoL of family caregivers who provide care for people with ADRD and b) help caregivers manage their stress and cope better with their lives. The SBP is implemented using a Master Trainer/Group Facilitator (lay leader) model. The SBP is a multi-component intervention that meets for 90 minutes once a week for 9 consecutive weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBP SPANISH
Description: The SBP caregiver intervention has been successfully delivered and disseminated in the US. It is currently offered in 9 states and 16 Texas counties . The SBP is designed to a) improve the QoL of family caregivers who provide care for people with ADRD and b) help caregivers manage their stress and cope better with their lives. The SBP is implemented using a Master Trainer/Group Facilitator (lay leader) model. The SBP is a multi-component intervention that meets for 90 minutes once a week for 9 consecutive weeks. The Spanish translation and cultural adaptation of the SBP has been completed under the direction of the PI.
Study: NCT04452669

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)
Description: VentaProst delivered for up to 10 days via mechanical ventilation at a dose range that may be up or down titrated to a patient's clinical condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)
Description: VentaProst delivered for up to 10 days via mechanical ventilation at a dose range that may be up or down titrated to a patient's clinical condition.
Study: NCT01200641

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups).
Study: NCT03679793

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Release Group
Description: Open surgical release of the A1 pulley is the gold standard of treating symptomatic trigger finger

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Release Group
Description: Percutaneous release is a minimal invasive alternative surgical procedure
Study: NCT02297126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic Intervention Arm (pharmacogenetic testing)
Description: In the design of this trial, pharmacogenetic testing will be triggered by the incident prescription of one or more of the targeted medications listed in the control arm. The pharmacogenetic array to be used incorporates 51 genetic variants for the following 16 genes/transporters: ATP-binding cassette sub-family C member 2, ATP-binding cassette, sub-family C, member 4, Cytochrome P450 2B6, Cytochrome P450 2C19, Cytochrome P450 2C9, Cytochrome P450 2D6, Cytochrome P450 3A4/3A5, Cytochrome P450 4F2, Dihydropyrimidine dehydrogenase, Glucose-6-Phosphate Dehydrogenase, Human Leukocyte antigen-B, I interleukin-28B, Inosine Triphosphatase, Solute Carrier Organic Anion Transporter Family, Member 1B, Thiopurine methyltransferase and V vitamin K epoxide reductase complex, subunit 1.
Study: NCT02472353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will begin to be administered prior to treatment with doxorubicin. Metformin will continue to be given throughout doxorubicin cycles until the completion of doxorubicin therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Standard of care treatment with doxorubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Standard of care treatment with doxorubicin
Study: NCT00042211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Treatment
Description: Brief Cognitive Behavioral Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: No treatment control
Study: NCT04179214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic manipulation
Description: Session will be performed twice a week for a three week period if a pop sound occurred then the therapist moved on next procedure ,if not subject will be repositioned and technique will performed again. This procedure will be performed for maximum of two attempts. Approximately 3 minutes of time is required to complete thrust manipulation subjects assigned to thrust manipulation also received general exercise program and manual pressure release technique as the control group. General exercise group involve Stretching exercises for the pectoral muscles and resisted strengthening exercises for the scapular retractors and elevators and the glenohumeral abductors and external rotators were performed three times per week for 3 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional pt protocol
Description: This group will receive manual pressure release technique along with general exercises program. General exercise group involve Stretching exercises for the pectoral muscles and resisted strengthening exercises for the scapular retractors and elevators and the glenohumeral abductors and external rotators were performed three times per week for 3 weeks.
Study: NCT01730313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Valproate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Valproate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01334359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: 9-month afterschool program designed to increase physical activity and aerobic fitness.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physical Activity
Description: 9-month afterschool program designed to increase physical activity and aerobic fitness.
Study: NCT01348243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: disodium clodronate 200 mg/4 ml with 1% lidocaine
Description: CLODRONATE 200 MG/4 ML SOLUTION FOR INTRAMUSCULAR USE WITH 1% LIDOCAINE EVERY OTHER WEEK

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Disodium clodronate 100 mg/3,3 ml with 1% lidocaine
Description: CLODRONATE 100 MG/3,3 ML SOLUTION FOR INTRAMUSCULAR USE WITH 1% LIDOCAINE ONCE-WEEK
Study: NCT00710658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WebChoice
Description: Patients in the experimental group had over the study period access to the Internet support system WebChoice that allowed them to monitor symptoms over time, and provided access to evidence-based self-management options tailored to their reported symptoms as well as a communication area where patients could ask questions to a clinical nurse specialist in cancer care and exchange experiences with other cancer patients.~Patients in the control group received usual care
Study: NCT04173949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 MG
Description: 3 month of treatment with daily Ramipril 2.5 MG
Study: NCT04474106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shock waves
Description: The shockwave generator orthogold 100® generates high-energy acoustic waves that behave much like other sound waves except that they have much greater pressure and energy. As with sound waves, Spark Waves® can easily travel great distance as long as the acoustic impedance stays the same.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: dummy head
Description: The shockwave generator orthogold 100® will be used in combination with a dummy head, to Refrain shock waves
Study: NCT00805688

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Questionnaires including symptom review (MDSAI-GI) via personal or telephone interviews (interactive voice response telephone system - IVRS)

Intervention type: PROCEDURE
Intervention: Blood Draws
Description: Blood sample (3½ tbs.)to measure levels of cytokines (biomarkers in the blood) and DNA (the genetic material in cells) before treatment starts.

Intervention type: DEVICE
Intervention: Pedometer
Description: Worn daily to measure physical activity.
Study: NCT02682121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 850 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily
Study: NCT01997580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: SSRI antidepressant
Study: NCT02309359

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0061

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0061

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0061

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Stable background dose of commercially available methotrexate (not provided by the Sponsor).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Stable background dose of commercially available methotrexate (not provided by the Sponsor).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Stable background dose of commercially available methotrexate (not provided by the Sponsor).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Stable background dose of commercially available methotrexate (not provided by the Sponsor).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Stable background dose of commercially available methotrexate (not provided by the Sponsor).
Study: NCT00963235

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: Three doses of 13vPnC given 6 months apart.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Six blood draws pre-vaccination and 1 month post-vaccination, doses 1-3.
Study: NCT02038192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living with Hope Program
Description: The Living with Hope Program is based on the research team's grounded theory study Hope and Connection. The film  Connecting with Hope reflects the findings of the grounded theory study. Stories of the Present has been utilized in the team's previous research with family caregivers of persons with advanced cancer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stories of the Present
Description: Stories of the Present is a directed journaling activity in which participants write in a journal at the end of the day their challenges, hope and hope for tomorrow
Study: NCT00977145

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A combination of intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1
Description: Vaccine regimen: The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, 15. During cycle two, three vaccines will be administered over a 9-week period on days 24, 43, 64. All participants will receive 12-MP (100 mcg each peptide) plus Peptide-tet (Peptide-tet; 200 mcg) administered in Montanide ISA-51 VG adjuvant. The vaccine will be administered subcutaneously (1 ml) and intradermally (1ml) at a single vaccination site.~Intratumoral Interferon regimen: On day 22, patients will have one or more tumor sites injected with 0.5-2 million IU of IFN-gamma each, with a maximum dose of 2 million IU of IFN-gamma administered per patient. The number of lesions that are injected will be dependent on the availability and size of the lesions.
Study: NCT03871556

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: LOGIQ P6 Diagnostic Ultrasound
Description: Ultrasound measurements of subcutaneous fat thickness
Study: NCT02836769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation Consult (RC)
Description: The RC was designed to foster key contributors to self management in the participants. The RC is administered by a rehabilitation professional and consists of an initial one-hour face-to-face consult and follow-up appointment(s) 2-12 weeks later, either telephone or face-to-face. The initial consult consists of orientation, consultation, goal-setting, teaching cognitive strategies, introduction to online resources/action planning/planning coping responses, review/implementation intentions/scheduling follow-up. The follow-up consists of a reminder, reorientation, checking of progress on goals and plans, re-planning as necessary, and discharge or scheduling of further follow-up as necessary.
Study: NCT02631681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group based exercise
Description: Supervised group based combined aerobic and resistance training for 12 weeks as part of our normal clinical practice.
Study: NCT02916927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine IV Infusion
Description: Ketamine 0.3 mg/kg in 100mL normal saline minibag administered over 15 min and placebo 10 mL normal saline syringe administered over 1 minute.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine IV push
Description: Ketamine 0.3 mg/kg in 10 mL normal saline syringe administered over 1 minute and placebo 100mL normal saline minibag administered over 15 min.
Study: NCT01465269

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Interactive Structured Treatment
Description: GIST groups consist of 8 group participants and two group therapists. Group members receive the workbook and are asked to bring it to each session. During each of the 13, 1.5 hour sessions, key concepts from the previous session are reviewed, a new topic is discussed, strategies and skills are practiced interactively, and real-life social problems are addressed. Previously covered topics are integrated into each session through discussion and problem solving to provide repetition and reinforcement of information.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alternative Intervention
Description: Participants in the alternative treatment will attend 13 weekly classroom sessions, where they will view video presentations of the same curriculum topics covered in the GIST workbook. The group therapists will serve as moderators and will meet with participants individually. Group interaction will not be encouraged. Homework exercises will be offered but participants will not be asked to return their homework and will not receive any feedback.